Clarient, Inc.

Company Logo: 

Clarient, Inc. combines innovative diagnostic technologies with world-class pathology expertise to assess and characterize cancer. The rise of individualized medicine has created the need for a centralized resource to provide leading oncology diagnostic technologies, such as flow cytometry and molecular testing: Clarient is that resource. The company plans to develop and market new, proprietary “companion” diagnostic markers for therapeutics in breast, prostate, lung and colon cancers, and leukemia and lymphoma.